Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells ; volume:10 ; number:1 ; day:4 ; month:1 ; year:2024 ; pages:1-13 ; date:12.2024
Cell death discovery ; 10, Heft 1 (4.1.2024), 1-13, 12.2024
- Urheber
-
Todesca, Luca Matteo
Gerke, Matthias
Bulk, Emma Etmar
Bachmann, Magdalena
Rudersdorf, Alisa
Antonuzzo, Lorenzo
Pillozzi, Serena
Düfer, Martina
Szabo, Ildiko
Schwab, Albrecht
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41420-023-01776-5
- URN
-
urn:nbn:de:101:1-2024031910142096296354
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Todesca, Luca Matteo
- Gerke, Matthias
- Bulk, Emma Etmar
- Bachmann, Magdalena
- Rudersdorf, Alisa
- Antonuzzo, Lorenzo
- Pillozzi, Serena
- Düfer, Martina
- Szabo, Ildiko
- Schwab, Albrecht
- SpringerLink (Online service)
Ähnliche Objekte (12)
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
Functional expression of mitochondrial KCa3.1 channels in non-small cell lung cancer cells
Cell-Cell Channels
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
Functional expression of mitochondrial KCa3.1 channels in non-small cell lung cancer cells
Cell-Cell Channels
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
Functional expression of mitochondrial KCa3.1 channels in non-small cell lung cancer cells
Cell-Cell Channels
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer